Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD0292 SAD in Healthy Japanese Participants
NCT07222254Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2025
- Primary completion
- Jul 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AZD-0292 (2 arms), sponsored by AstraZeneca. Primary endpoint: Number of participants with adverse events (AEs), serious adverse events (SAEs) and adverse event of special interest (AESI) at Day 161. Started Dec 2025; status: completed.
02
Drugs
AZD-0292
Beyond the preview
Go deeper on NCT07222254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07222254.